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Abstract
© 2016 American Association for Cancer Research.The majority of patients with melanoma
harbor mutations in the BRAF oncogene, thus making it a clinically relevant target. However,
response  to  mutant  BRAF  inhibitors  (BRAFi)  is  relatively  short-lived  with  progression-free
survival  of  only  6  to  7  months.  Previously,  we reported high expression of  ribonucleotide
reductase M2 (RRM2), which is rate-limiting for de novo dNTP synthesis, as a poor prognostic
factor in patients with mutant BRAF melanoma. In this study, the notion that targeting de novo
dNTP synthesis through knockdown of RRM2 could prolong the response of melanoma cells to
BRAFi was investigated. Knockdown of RRM2 in combination with the mutant BRAFi PLX4720 (an
analog  of  the  FDA-approved drug  vemurafenib)  inhibited  melanoma cell  proliferation  to  a
greater extent than either treatment alone. This occurred in vitro in multiple mutant BRAF cell
lines  and  in  a  novel  patient-derived  xenograft  (PDX)  model  system.  Mechanistically,  the
combination increased DNA damage accumulation, which correlated with a global decrease in
DNA  damage  repair  (DDR)  gene  expression  and  increased  apoptotic  markers.  After
discontinuing PLX4720 treatment, cells showed marked recurrence. However, knockdown of
RRM2  attenuated  this  rebound  growth  both  in  vitro  and  in  vivo,  which  correlated  with
maintenance of the senescence-associated cell-cycle arrest. Implications: Inhibition of RRM2
converts the transient response of melanoma cells to BRAFi to a stable response and may be a
novel combinatorial strategy to prolong therapeutic response of patients with melanoma.
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